Ganglioside GT1b (bovine) (sodium salt)
(Synonyms: Ganglioside G1, Trisialoganglioside GT1b) 目录号 : GC52505A sphingolipid
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ganglioside GT1b is a trisialoganglioside that is characterized by having two sialic residues linked to the inner galactose unit. It binds to the neurotoxins botulinum toxin serotype A (BTxA), BTxA heavy chain, and tetanus toxin with IC50 values of 11, 0.74, and 7.2 μM, respectively.1 Ganglioside GT1b-containing liposomes bind to the major coat protein VP1 from Merkel cell polyomavirus (MCPyV), which has been identified in Merkel cell carcinomas, identifying ganglioside GT1b as a putative MCPyV receptor.2 Ganglioside GT1b decreases production of IL-6, IL-10, IgG, IgM, and IgA in human peripheral blood mononuclear cells (PBMCs) by 31.4, 30.5, 60, 59.5, and 58%, respectively, when used at a concentration of 10 μM.3 This product contains ganglioside GT1b molecular species with variable fatty acyl chain lengths. As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1558]
1.Schengrund, C.-L., DasGupta, B.R., and Ringler, N.J.Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereofJ. Neurochem.57(3)1024-1032(1991) 2.Erickson, K.D., Garcea, R.L., and Tsai, B.Ganglioside GT1b is a putative host cell receptor for the Merkel cell polyomavirusJ. Virol.83(19)10275-10279(2009) 3.Kanda, N., and Tamaki, K.Ganglioside GT1b suppresses immunoglobulin production by human peripheral blood mononuclear cellsImmunology96(4)628-633(1999)
Cas No. | SDF | Download SDF | |
别名 | Ganglioside G1, Trisialoganglioside GT1b | ||
Canonical SMILES | CCCCCCCCCCCCC/C=C/[C@]([H])([C@](NC(CCCCCCCCCCCCCCCCC)=O)([H])CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2O[C@@H]([C@@H]([C@@H]([C@H]2O)O[C@@]3(C([O-])=O)O[C@H]([C@@H]([C@H](C3)O)NC(C)=O)[C@H](O)[C@H](O[C@@]4(C([O-])=O)O[C@H]([C@@H]([C@H](C4)O)NC(C)=O)[C@H](O)[C@H](O)CO)CO)O[C@H]5[C@@H]([C@H]([C@H]([C@H](O5)CO)O)O[C@@H]6O[C@@H]([C@@H]([C@@H]([C@H]6O)O[C@@]7(C([O-])=O)O[C@H]([C@@H]([C@H](C7)O)NC(C)=O)[C@H](O)[C@H](O)CO)O)CO)NC(C)=O)CO)O)O)O.[Na+].[Na+].[Na+] | ||
分子式 | C95H162N5O47 • 3Na (for stearoyl) | 分子量 | 2126.3 |
溶解度 | Chloroform:Methanol (2:1): Soluble,Water: micellar aggregates | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.4703 mL | 2.3515 mL | 4.703 mL |
5 mM | 0.0941 mL | 0.4703 mL | 0.9406 mL |
10 mM | 0.047 mL | 0.2352 mL | 0.4703 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。